Myriad Genetics, Inc.NASDAQ: MYGN

Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026

· Issued by Myriad Genetics, Inc. via GlobeNewswire

Summary by 6ix AI

Myriad Genetics, Inc., which develops molecular diagnostic tests, will release its second quarter 2026 earnings after the market closes on Thursday, July 30, 2026, and hold a conference call at 4:30 pm ET that day.

Key details

  • Management will give a financial overview and business update on the company's performance for the second quarter of 2026 during the call.
  • A live webcast will be available on Myriad's Investor Relations website, with an archived webcast available there after the call; telephone participants register to receive a dial-in number and unique PIN.

6ix AI wrote this summary from the release below and checked it against the release.

SALT LAKE CITY, July 23, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2026 earnings conference call at 4:30 pm ET on Thursday, July 30, 2026. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the second quarter of 2026.

A live webcast of the conference call can be accessed on Myriad’s Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available at investor.myriad.com following the call.

About Myriad Genetics 
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit myriad.com.

Investor Contact 
Matt Scalo 
(801) 584-3532 
[email protected]

Media Contact 
Andria Rosell
(385) 202-3510
[email protected]

Myriad Genetics, Inc. on 6ix

Story so far

Earlier from Myriad Genetics

Later from Myriad Genetics

All Myriad Genetics news releases